Percutaneous closure of patent foramen ovale: safe and effective but underutilized

Expert Rev Cardiovasc Ther. 2015 Feb;13(2):121-3. doi: 10.1586/14779072.2015.1000305. Epub 2015 Jan 5.

Abstract

With three recently published randomized trials on patent foramen ovale (PFO) closure, the concept of PFO closure to reduce recurrent strokes has been proven; however, PFO closure is currently only considered for secondary prevention. Given the potential devastating consequences of a PFO-related event, we advocate screening for and closure of a PFO for primary prevention in high-risk populations. Such populations include patients who are suffering from a disease that is associated with PFO (e.g., migraine) or patients with high-risk hobbies/professions (e.g., weight-lifters, frequent-flyers, and deep sea divers). Looking at young people with a remaining average life expectancy of 50 years, we have to close 2.4 PFOs to prevent one stroke. This should support a more proactive attitude toward PFO screening and closure.

Keywords: migraine; patent foramen ovale; percutaneous PFO closure; prevention; stroke.

Publication types

  • Case Reports
  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Cardiac Catheterization / instrumentation
  • Female
  • Foramen Ovale, Patent / diagnosis
  • Foramen Ovale, Patent / prevention & control*
  • Foramen Ovale, Patent / therapy
  • Humans
  • Secondary Prevention / trends*
  • Septal Occluder Device / trends*
  • Stroke / prevention & control*
  • Stroke / therapy
  • Treatment Outcome